» Articles » PMID: 21414671

En Route to New Blockbuster Anti-histamines: Surveying the Offspring of the Expanding Histamine Receptor Family

Overview
Specialty Pharmacology
Date 2011 Mar 19
PMID 21414671
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

With the recognition of two new histamine receptors at the start of the new millennium, the field of histamine research has seen a clear revival. In the last 10 years, many academic and industrial groups have taken up the challenge to target these new members of the aminergic G-protein-coupled receptor (GPCR) family. Histamine receptor research nicely illustrates how GPCR research has changed in the post-genomic era. There is a growing understanding of GPCR structure, function and modulation at a molecular level. Emerging concepts such as receptor isoforms, GPCR oligomerization and ligand-biased signaling are all being studied, but their clinical relevance remains to be determined. The histamine H(3) and H(4) drug development programs can help to establish the link between these molecular features and clinical efficacy. Several new anti-histamines are now being tested for diverse clinical applications and are poised to become the next blockbuster drugs targeting histamine receptors.

Citing Articles

A Machine Learning Algorithm Suggests Repurposing Opportunities for Targeting Selected GPCRs.

El-Atawneh S, Goldblum A Int J Mol Sci. 2024; 25(18).

PMID: 39337714 PMC: 11432050. DOI: 10.3390/ijms251810230.


Synthesis and Pharmacological Characterization of New Photocaged Agonists for Histamine H and H Receptors.

Zheng Y, Gao M, Wijtmans M, Vischer H, Leurs R Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675496 PMC: 11053687. DOI: 10.3390/ph17040536.


Structural basis for recognition of antihistamine drug by human histamine receptor.

Peng X, Yang L, Liu Z, Lou S, Mei S, Li M Nat Commun. 2022; 13(1):6105.

PMID: 36243875 PMC: 9569329. DOI: 10.1038/s41467-022-33880-y.


KSK-74: Dual Histamine H and Sigma-2 Receptor Ligand with Anti-Obesity Potential.

Mika K, Szafarz M, Zadrozna M, Nowak B, Bednarski M, Szczepanska K Int J Mol Sci. 2022; 23(13).

PMID: 35806019 PMC: 9266460. DOI: 10.3390/ijms23137011.


High-Dose Betahistine Improves Cognitive Function in Patients With Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial.

Wang Y, Huang X, Fan H, An H, Ma T, Zhang Q Front Psychiatry. 2021; 12:762656.

PMID: 34790138 PMC: 8591287. DOI: 10.3389/fpsyt.2021.762656.